Pharmaceutical

ESC 2024: Latest FLOW trial analysis highlights how Ozempic can benefit CKD patients

If approved, Novo Nordisk's Ozempic will become the first GLP-1 therapy option for patients with type 2 diabetes and chronic kidney disease.

Aug 31, 2024 - 04:00
ESC 2024: Latest FLOW trial analysis highlights how Ozempic can benefit CKD patients
If approved, Novo Nordisk's Ozempic will become the first GLP-1 therapy option for patients with type 2 diabetes and chronic kidney disease.
Read the original article

Tags:

Previous Article

Low-quality video target detection based on EEG signal using eye movement alignment

Next Article

J&J targets generalised myasthenia gravis landscape with nipocalimab

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Wegovy is usually taken indefinitely. Amgen wants a version that can be tapered down

STAT+: Wegovy is usually taken indefinitely. Amgen want...

Feb 5, 2024

STAT+: Bright Health looks to get out of health insurance entirely

STAT+: Bright Health looks to get out of health insuran...

Apr 29, 2023

Editas grabs orphan drug status for sickle cell disease CRISPR therapy

Editas grabs orphan drug status for sickle cell disease...

Apr 28, 2023